This liposomal capsule format is designed to support stability and daily use as part of a balanced lifestyle
WEGOVY has been a dominant force in the lucrative obesity market, which is poised to reach $12 billion by 2034 in the US, as per DelveInsight
The approval of Wegovy represents a turning point for healthcare providers to embrace medical management of obesity to help improve chronic weight management for patients. For more than two decades, Novo Nordisk has led the charge to translate the complex science behind obesity into medicines that can make a difference, all while partnering across industries and sectors to change how obesity is understood, diagnosed and treated, said Doug Langa, executive vice president, North America operations and president of Novo Nordisk Inc
Gut-friendly hydration with zing - Sachets dissolve easilyjust stir into 150 ml of water (add ice for extra freshness) to sip on-the-go
Comparing Incidence Rates When comparing the incidence of dizziness in patients taking semaglutide to those on other diabetes and obesity medications, it is important to consider the variability in side effect profiles among different drugs
[PubMed] Esposito S, et al